Outcomes in idiopathic pulmonary fibrosis: A meta-analysis from placebo controlled trials

Atkins, Chris; Loke, Yoon K.; Wilson, Andrew M.

doi:10.1016/j.rmed.2013.11.007

Cited by 75 publications

(47 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This study confirmed the predictive value of absolute baseline FVC or %pFVC, which has been consistently shown in the literature . This finding suggested that acute exacerbations are more likely to occur in patients with more advanced disease, and a similar conclusion was drawn from a meta‐analysis of placebo‐controlled trials that acute exacerbations were less commonly observed in trials that excluded severe disease than those that did not . The parameter %pDL CO was shown to be a significant predictor of acute exacerbations in some studies, although this finding was not confirmed in several other reports .…”

Section: Discussionsupporting

confidence: 81%

Parametric Time‐to‐Event Model for Acute Exacerbations in Idiopathic Pulmonary Fibrosis

Tang

Weber

Stowasser

et al. 2020

CPT Pharmacom & Syst Pharma

View full text Add to dashboard Cite

We describe a parametric time‐to‐event model for idiopathic pulmonary fibrosis (IPF) exacerbations and identify predictors of exacerbation risk using data obtained for the tyrosine‐kinase inhibitor nintedanib in two phase III studies (INPULSIS‐1/2). Parametric survival analysis was performed on time to first exacerbation (censoring on day 372), with univariate analysis to select statistically significant covariates (P = 0.05). Multivariate covariate models were developed using stepwise covariate modeling with forward inclusion (P = 0.05) and backward elimination (P = 0.01). Sixty‐three first exacerbation events were reported across 1,061 subjects in the INPULSIS studies. Baseline and decline of forced vital capacity (FVC)/percent‐predicted FVC (%pFVC), supplemental oxygen use, baseline CO diffusing capacity and age were statistically significant in the univariate analysis. The final covariate model included decline in FVC to week 52, baseline %pFVC, supplemental oxygen use, and age. The developed model may be used to identify patients at high risk of IPF exacerbations and accelerate development of novel treatments.

show abstract

Section: Discussionsupporting

confidence: 81%

Parametric Time‐to‐Event Model for Acute Exacerbations in Idiopathic Pulmonary Fibrosis

Tang

Weber

Stowasser

et al. 2020

CPT Pharmacom & Syst Pharma

View full text Add to dashboard Cite

show abstract

“…The study was thereafter aborted for ethical reasons related to this difference [7]. Because the frequency of AE-IPF has been reported to be influenced by disease severity [23], differences in the eligibility criteria or patient population in these studies are a possible explanation for the discrepancy. Further studies are needed to clarify the ability of pirfenidone to prevent AE-IPF.…”

Section: Discussionmentioning

confidence: 99%

Risk factors for acute exacerbation of idiopathic pulmonary fibrosis – Extended analysis of pirfenidone trial in Japan

Kondoh

Taniguchi

Ebina³

et al. 2015

Respiratory Investigation

View full text Add to dashboard Cite

“…In a recent meta-analysis, this occurred with a frequency of 41 cases per 1000 patient-years [11]. HRCT is often obtained in the work-up of IPF patients with acute symptoms.…”

Section: Usual Interstitial Pneumoniamentioning

confidence: 99%

The role of high-resolution computed tomography in the follow-up of diffuse lung disease

2017

View full text Add to dashboard Cite

High-resolution computed tomography (HRCT) of the lung is a key component of the multidisciplinary approach to diagnosis in diffuse lung disease (DLD). HRCT also plays an important role in the follow-up of patients with established DLD. In this respect, serial HRCT examinations may provide valuable information that cannot be determined from clinical history and other diagnostic tests, such as pulmonary function tests. Important roles of HRCT in this context include assisting in determining prognosis, monitoring for the efficacy of treatment, detecting progression of disease or complications, and evaluating patients with worsening or acute symptoms. Both clinicians and radiologists should be aware of the expected evolution of HRCT changes in a variety of DLDs. The goals of this paper are to discuss: 1) the expected evolution of HRCT findings over time in common DLDs; 2) the role of serial HRCT examinations in formulating an initial diagnosis; and 3) the role of HRCT in the follow-up of patients with known DLD.

show abstract

Outcomes in idiopathic pulmonary fibrosis: A meta-analysis from placebo controlled trials

Abstract: Mortality is heterogeneous and dependent on entry criteria. Infection rates were high, both with and without immunosuppression, and were higher in severe disease. Consideration should be given to alternative outcomes to mortality in future IPF trials if severe disease is excluded.

Cited by 75 publications

References 36 publications

Parametric Time‐to‐Event Model for Acute Exacerbations in Idiopathic Pulmonary Fibrosis

Parametric Time‐to‐Event Model for Acute Exacerbations in Idiopathic Pulmonary Fibrosis

Risk factors for acute exacerbation of idiopathic pulmonary fibrosis – Extended analysis of pirfenidone trial in Japan

The role of high-resolution computed tomography in the follow-up of diffuse lung disease

Contact Info

Product

Resources

About